-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor-in-Chief | Xi According to the latest global cancer data in 2020, breast cancer has surpassed lung cancer to become the world's largest canc.
Triple-negative breast cancer (TNBC) is insensitive to endocrine drugs and HER2-targeting drugs because of its negative surface estrogen receptor, progesterone receptor and HERCurrently, surgery and chemotherapy are the main treatmen.
At the same time, triple-negative breast cancer also has the characteristics of strong invasiveness, rapid remote metastasis and high local recurrence rate, and has become the most difficult subtype of breast cancer to treat clinical.
Therefore, it has important clinical application value and far-reaching social significance to deeply explore the occurrence and development of triple-negative breast cancer, explore new therapeutic targets and strategies, and improve the survival rate and quality of life of triple-negative breast cancer patien.
Epigenetic modification has become a frontier field of tumor research in recent yea.
Currently, a large number of small-molecule enzyme inhibitors or activators involving epigenetic regulatory pathways are being developed for clinical u.
However, with the exception of a few types of solid tumors, T-cell lymphoma, epithelioid sarcoma, and refractory follicular lymphoma, epigenetic drugs are often poorly effective in advanced tumo.
A growing body of research and clinical data suggest that a combination of epigenetic drugs and immunotherapy holds promise for a range of patients with solid cance.
On May 16, 2022, Wu Qin's team from the Institute of Basic Medicine and Oncology, Chinese Academy of Sciences, in collaboration with the University of Toronto, Canada, published a research paper titled PRMT inhibition triggers the viral mimicry response in Triple Negative Breast Cancer online in Nature Chemical Biology, revealing that The new mechanism of arginine methyltransferase regulating endogenous immunity provides a new strategy for the immunotherapy of triple-negative breast canc.
The authors first systematically screened triple-negative breast cancer using epigenetic small-molecule inhibitors and identified arginine methyltransferase as a possible new therapeutic targ.
Combined with the methods of chemical biology, cell biology and bioinformatics, the mechanism of action was deeply discussed, and it was found that targeting arginine methyltransferase can regulate alternative splicing in cells, resulting in a large number of intron retenti.
, the retained introns form double-stranded RNAs that activate downstream receptors and upregulate the interferon pathway, thereby triggering an endogenous immune response that leads to cell dea.
This study revealed a new mechanism by which arginine methyltransferase regulates endogenous antiviral immunity in cells, providing a new target for the treatment of triple-negative breast canc.
In addition, this study also shows that the endogenous immune regulatory function of arginine methyltransferase is limited to some triple-negative breast cancer cel.
These cells have the characteristics of high expression of the interferon pathway in the backgrou.
Inhibition of arginine methyltransferase activates the above interferon pathway, so that the triple-negative breast cancer cells whose background interferon pathway is up-regulated exceeds the tolerance thresho.
cause cell dea.
Therefore, the activation status of the background interferon pathway can be used as a biomarker to predict the sensitivity of arginine methyltransferase inhibito.
In conclusion, this study revealed a new therapeutic target for triple-negative breast cancer, arginine methyltransferase, and revealed a new mechanism for its regulation of cell proliferation and immunity, providing new insights for the immunotherapy of triple-negative breast canc.
strate.
It is worth mentioning that Nature Chemical Biology also published the News & Views article Putting introns on retainer by Stéphane Richard of McGill University in Canada during the same peri.
Wu Qin is a researcher in the team of Academician Tan Weihong, Institute of Basic Medicine and Oncology, Chinese Academy of Scienc.
Zhejiang Province overseas high-level talents, winner of Zhejiang Province Outstanding Youth Fu.
Mainly engaged in the research of chemical molecular probes and tumor precision thera.
The research group is committed to using chemical biology, cell biology, molecular biology and bioinformatics to identify new targets for breast cancer treatment, draw molecular maps of breast cancer cells, and identify new immune regulation mechanisms of breast canc.
, to develop biomarkers to predict drug effects and achieve personalized and precise treatment of breast canc.
The research results were published as the first/corresponding author in journals such as Nature Chemical Biology, Nature Reviews Drug Discovery, Nature Communications, and Chemical Scien.
The research group has been recruiting outstanding postdoctoral fellows for a long time, and the salary is genero.
Resume delivery (if you are interested, please send your resume and other materials to): https://jinshu.
net/f/ZqXwZt or scan the QR code to submit your resume original link: https:// 022-01024-4 https:// Publisher: 11 Reprint Notice [Non-original article] The copyright of this article belongs to the author of the article, and you are welcome to repost and share without the auth.
Reprinting is prohibited with the permission of the author, and the author has all legal rights, and offenders will be held accountab.
Triple-negative breast cancer (TNBC) is insensitive to endocrine drugs and HER2-targeting drugs because of its negative surface estrogen receptor, progesterone receptor and HERCurrently, surgery and chemotherapy are the main treatmen.
At the same time, triple-negative breast cancer also has the characteristics of strong invasiveness, rapid remote metastasis and high local recurrence rate, and has become the most difficult subtype of breast cancer to treat clinical.
Therefore, it has important clinical application value and far-reaching social significance to deeply explore the occurrence and development of triple-negative breast cancer, explore new therapeutic targets and strategies, and improve the survival rate and quality of life of triple-negative breast cancer patien.
Epigenetic modification has become a frontier field of tumor research in recent yea.
Currently, a large number of small-molecule enzyme inhibitors or activators involving epigenetic regulatory pathways are being developed for clinical u.
However, with the exception of a few types of solid tumors, T-cell lymphoma, epithelioid sarcoma, and refractory follicular lymphoma, epigenetic drugs are often poorly effective in advanced tumo.
A growing body of research and clinical data suggest that a combination of epigenetic drugs and immunotherapy holds promise for a range of patients with solid cance.
On May 16, 2022, Wu Qin's team from the Institute of Basic Medicine and Oncology, Chinese Academy of Sciences, in collaboration with the University of Toronto, Canada, published a research paper titled PRMT inhibition triggers the viral mimicry response in Triple Negative Breast Cancer online in Nature Chemical Biology, revealing that The new mechanism of arginine methyltransferase regulating endogenous immunity provides a new strategy for the immunotherapy of triple-negative breast canc.
The authors first systematically screened triple-negative breast cancer using epigenetic small-molecule inhibitors and identified arginine methyltransferase as a possible new therapeutic targ.
Combined with the methods of chemical biology, cell biology and bioinformatics, the mechanism of action was deeply discussed, and it was found that targeting arginine methyltransferase can regulate alternative splicing in cells, resulting in a large number of intron retenti.
, the retained introns form double-stranded RNAs that activate downstream receptors and upregulate the interferon pathway, thereby triggering an endogenous immune response that leads to cell dea.
This study revealed a new mechanism by which arginine methyltransferase regulates endogenous antiviral immunity in cells, providing a new target for the treatment of triple-negative breast canc.
In addition, this study also shows that the endogenous immune regulatory function of arginine methyltransferase is limited to some triple-negative breast cancer cel.
These cells have the characteristics of high expression of the interferon pathway in the backgrou.
Inhibition of arginine methyltransferase activates the above interferon pathway, so that the triple-negative breast cancer cells whose background interferon pathway is up-regulated exceeds the tolerance thresho.
cause cell dea.
Therefore, the activation status of the background interferon pathway can be used as a biomarker to predict the sensitivity of arginine methyltransferase inhibito.
In conclusion, this study revealed a new therapeutic target for triple-negative breast cancer, arginine methyltransferase, and revealed a new mechanism for its regulation of cell proliferation and immunity, providing new insights for the immunotherapy of triple-negative breast canc.
strate.
It is worth mentioning that Nature Chemical Biology also published the News & Views article Putting introns on retainer by Stéphane Richard of McGill University in Canada during the same peri.
Wu Qin is a researcher in the team of Academician Tan Weihong, Institute of Basic Medicine and Oncology, Chinese Academy of Scienc.
Zhejiang Province overseas high-level talents, winner of Zhejiang Province Outstanding Youth Fu.
Mainly engaged in the research of chemical molecular probes and tumor precision thera.
The research group is committed to using chemical biology, cell biology, molecular biology and bioinformatics to identify new targets for breast cancer treatment, draw molecular maps of breast cancer cells, and identify new immune regulation mechanisms of breast canc.
, to develop biomarkers to predict drug effects and achieve personalized and precise treatment of breast canc.
The research results were published as the first/corresponding author in journals such as Nature Chemical Biology, Nature Reviews Drug Discovery, Nature Communications, and Chemical Scien.
The research group has been recruiting outstanding postdoctoral fellows for a long time, and the salary is genero.
Resume delivery (if you are interested, please send your resume and other materials to): https://jinshu.
net/f/ZqXwZt or scan the QR code to submit your resume original link: https:// 022-01024-4 https:// Publisher: 11 Reprint Notice [Non-original article] The copyright of this article belongs to the author of the article, and you are welcome to repost and share without the auth.
Reprinting is prohibited with the permission of the author, and the author has all legal rights, and offenders will be held accountab.
